Board of Directors
The Board of Directors have been involved in regulatory approval and commercialization of devices and treatments for heart failure and heart disease globally. They also have significant connections with leading global medical device companies including Medtronic, Johnson & Johnson, Boston Scientific, Baxter Healthcare and Edwards Lifesciences.
Chief Executive Officer and President; Chairman of the Board
John Erb has over 40 years of experience in the medical device industry. Mr. Erb is co-founder of NuAx, Inc. (formerly Cardia Access, Inc.), a medical device company involved in developing new devices for the treatment of heart disease.
From 2001 through 2006, Mr. Erb was Chief Executive Officer of CHF Solutions, Inc., a medical device company focused on the treatment of congestive heart failure. CHF Solutions, Inc. was acquired by Gambro. From 1997 through 2001, Mr. Erb was President and Chief Executive Officer of IntraTherapeutics, Inc., a medical device company involved in the development, manufacturing and distribution of peripheral vascular stents. IntraTherapeutics, Inc. was acquired by Sulzer Medica.
Previously, Mr. Erb was Vice President of Operations for Schneider Worldwide, a division of Pfizer, Inc. Mr. Erb spent 10 years with Johnson & Johnson’s Iolab Division and started his career with American Hospital Supply Corporation.
Mr. Erb serves as Chairman of the Board of Directors for Vascular Solution, Inc., a public NASDAQ company and Chairman of the Board of Directors for Osprey Medical, a public ASX company. Mr. Erb previously served on the Board of Directors of CryoCath Technologies, acquired by Medtronic in 2008 and SenoRx, Inc., acquired by CR Bard in 2010.
Mr. Erb has a bachelor’s degree in business administration from California State University, Fullerton.
Mr. Brandt is a senior executive with over 35 years of experience in the healthcare industry. Mr. Brandt was employed by Thoratec Corporation from November 2004 to October 2015, serving as Vice President Global Sales and Marketing, Vice President of Global Sales and Vice President International Sales. Prior to Thoratec, Mr. Brandt was Vice President Sales & Marketing for CHF Solutions from October 2002 to November 2004 and Vice President Global Marketing, Cardiovascular Surgery Division for St. Jude Medical from November 2000 to October 2002. Mr. Brandt received his B.S. from Franklin Pierce College.
Mr. Likens is a principal at Likens Healthcare and Management Consulting, LLC. He was the President and CEO of Ulthera, Inc. from 2006 to 2016. Prior to Ulthera, Mr. Likens was employed at GMP Companies, Inc. as President of GMP Wireless Medicine from 2001 to 2006 and Executive Vice President, Operations from 2001 to 2004. Mr. Likens previously served in various capacities at Baxter Healthcare Corporation from 1978 to 2001, and was President of Baxter’s Renal U.S. business upon his departure in January, 2001. Mr. Likens has a B.B.A. in Marketing from Kent State University.
Jon Salveson is the Vice Chairman, Investment Banking and Chairman of the Healthcare Investment Banking Group at Piper Jaffray. Mr. Salveson joined Piper Jaffray in 1993 and became a Managing Director in 1999. He was named the Group Head of Piper Jaffray’s healthcare investment banking group in 2001.
He then was appointed Global Head of Investment Banking and a member of the Executive Committee of Piper Jaffray in 2004. He has served as Vice Chairman of Investment Banking at Piper Jaffray since 2010. Throughout his career at Piper Jaffray, Mr. Salveson’s area of practice has focused on the medical device industry.
Mr. Salveson started his career as a market manager at Bio-Metrics Systems (now part of Surmodics, Inc), an innovator in medical device surface modification, where he gained experience working in cardiology and interventional medicine. Currently, he serves on the Board of Directors at the Minnesota Orchestra since 2007 and CyroLife Inc. since 2012. In addition, he serves on the Board of Regents for St. Olaf College since 2011.
Mr. Salveson received his M.M.M. in finance from the Kellogg Graduate School of Management at Northwestern University and a B.A. in chemistry and religion from St. Olaf College.
Mr. Waller has over 35 years of financial and management experience with an emphasis in financial management, accounting, treasury and mergers/acquisitions. He was Chief Financial Officer of Universal Building Products, a manufacturer of concrete construction accessories, from March, 2006 until April of 2011 where he implemented several cost savings initiatives that saved the company several million dollars. Previous to this position, he had been in retirement except for board of director positions. Prior, Mr. Waller served as the Chief Financial Officer, Vice President of Finance and Treasurer of Sybron Dental Specialties, Inc., a manufacturer and marketer of consumable dental products. At Sybron he was instrumental in a variety of initiatives including being instrumental in the IPO of the company, over 30 company acquisitions worldwide and sales growth from $10 million to over $750 million during his twenty-five year tenure at Sybron. He was the Vice President of European Operations for Kerr (a subsidiary of Sybron) and Vice President and Controller at Ormco (also a subsidiary of Sybron) during his time at Sybron. Mr. Waller has an MBA with a concentration in accounting from California State University, Fullerton.
Mr. Waller currently serves as a board member and audit committee chairman for Endologix, Inc. He previously served as board member and audit committee chairman for Alsius, Inc., Biolase, Inc., Cardiogenesis Inc., Clarient, Inc. and SenRx, Inc., all publicly traded companies.
Warren S. Watson
Mr. Watson is a medical device executive with over 35 years of med tech experience. Mr. Watson’s career began with Medtronic, Inc. where he served in capacities of increasing responsibility for greater than 30 years. Mr. Watson focused in the Cardiac Rhythm Management, Cardiac Ablation, Heart Failure and Cardiology fields including positions in technical management, clinical and regulatory responsibilities, business development, strategic and marketing responsibilities, and general management. Mr. Watson served as VP of Research and Development for the Cardiac Rhythm Management business for over 8 years and was Chair of the Medtronic Corporate Research and Development Council. Mr. Watson retired from Medtronic with 33 years of service to the Company.
Following his retirement from Medtronic, Mr. Watson has served on multiple medical device, non-med tech and charitable organization Boards:
- Executive Chair of the Board of Directors for Cameron Health, Inc. Cameron Health is a California based medical device company developing a subcutaneous implantable defibrillator for patients at risk of sudden cardiac death. He served on the board until Cameron Health was purchased by Boston Scientific, Inc. in June, 2012.
- Board of Directors for Cardia Access, Inc. Cardia Access is a Minneapolis based early stage medical device company focused on development of innovative technology for endocardial cardiac leads.
- Board of Directors for Cardialen, Inc. Cardialen is a Minneapolis based early stage medical device company developing unique, non-ablative technology for the termination of atrial fibrillation.
- Advisor to the Office of Technology Commercialization at the University of Minnesota. He works closely with the Venture Center where he focuses on the launch of new medical device companies based on U of MN. Innovation.
- Board of Gillette Children’s Specialty Healthcare in St. Paul, MN. Gillette Children’s is a hospital system treating children with rare and disabling medical conditions.
- Board of Directors of Citizen’s Independent Bank of St. Louis Park, Minnesota. Citizen’s Independent Bank is a community based bank serving customers across the Twin Cities with four branch offices and over $300MM in assets.
Mr. Watson is a graduate of the University of Minnesota with undergraduate and graduate degrees in Electrical Engineering.